shares rise Baxter International on Thursday forecast 2025 profit above Wall Street estimates banking on strong sales of its medical devices, sending the company's shares up 7% in premarket trade.
Barclays analyst Matt Miksic maintained a Buy rating on Baxter International (BAX – Research Report) on March 7 and set a price target of $41.00. The company’s shares closed last Friday at $36.57.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback